Androgen deprivation therapy for precancerous lesions of the prostate

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 285-291

  Hull, David ^a   Bostwick, David G ^a  

^a BOSTWICK LABORATORIES   (United States)

Author keywords

adenocarcinoma; androgen deprivation therapy; finasteride; high grade PIN; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DUTASTERIDE; ESTROGEN RECEPTOR; FINASTERIDE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; MEGESTROL ACETATE; NILUTAMIDE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TOREMIFENE;

ADJUVANT THERAPY; APOPTOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HISTOPATHOLOGY; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; INCIDENCE; INHIBITION KINETICS; MALE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MITOSIS; MONOTHERAPY; NONHUMAN; NUCLEOLUS; ORCHIECTOMY; PATIENT SELECTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PRECANCEROUS CONDITIONS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 42949159287     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.006     Document Type: Review

References (42)

1. Bostwick DG N.R., Qian J., and Cheng L. Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention. European Urology 35 5-6 (1999) 492-495
2. Srigley J.R. Benign mimickers of prostatic adenocarcinoma. Modern Pathology 17 (2004) 328-348
3. Putzi M.J., and De Marzo A.M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56 (2000) 828-832
4. Postma R., Schroder F.H., and van der Kwast T.H. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology 65 (2005) 745-749
5. McNeal J.E. Morphogenesis of prostatic carcinoma. Cancer 18 (1965) 1659-1666
6. Prostatic intraepithelial neoplasia: significance and correlation with prostate-specific antigen and transrectal ultrasound. Proceedings of a workshop of the National Prostate Cancer Detection Project. March 13, 1989, Bethesda, Maryland. Urology 34 (1989) 2-69
7. McNeal J.E., and Bostwick D.G. Intraductal dysplasia: a premalignant lesion of the prostate. Human Pathology 17 (1986) 64-71
8. Epstein J.I., Grignon D.J., Humphrey P.A., et al. Inter-observer reproducibility in the diagnosis of prostatic intraepithelial neoplasia. American Journal of Surgical Pathology 19 (1995) 873-886
9. Bostwick D.G., Amin M.B., Dundore P., et al. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Human Pathology 24 (1993) 298-310
10. Sakr W.A., Billis A., Ekman P., et al. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scandinavian Journal of Urology and Nephrology Supplementum (2000) 11-18
11. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (Athens, Greece) 8 (1994) 439-443
12. Sakr W.A., Grignon D.J., Haas G.P., et al. Age and racial distribution of prostatic intraepithelial neoplasia. European Urology 30 (1996) 138-144
13. Sakr W.A., Haas G.P., Cassin B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. The Journal of Urology 150 (1993) 379-385
14. Rubin M.A., Zhou M., Dhanasekaran S.M., et al., Chinnaiyan A.M. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. The Journal of the American Medical Association 287 (2002) 1662-1670
15. Emmert-Buck M.R., Vocke C.D., Pozzatti R.O., et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Research 55 (1995) 2959-2962
16. Qian J., Bostwick D.G., Takahashi S., et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Research 55 (1995) 5408-5414
17. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 (1941) 293-297
18. Tolis G., Ackman D., Stellos A., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proceedings of the National Academy of Sciences of the United States of America 79 (1982) 1658-1662
19. Waxman J., Man A., Hendry W.F., et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. British Medical Journal (Clinical Research Ed.) 291 (1985) 1387-1388
20. Loumaye E., and Catt K.J. Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells. Science 215 (1982) 983-985
21. Goldenberg S.L., and Bruchovsky N. Use of cyproterone acetate in prostate cancer. The Urologic Clinics of North America 18 (1991) 111-122
22. Labrie F., Belanger A., Simard J., et al. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 71 (1993) 1059-1067
23. Labrie F., Dupont A., Belanger A., et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry 23 (1985) 833-841
24. Normington K., and Russell D.W. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. The Journal of Biological Chemistry 267 (1992) 19548-19554
25. Thigpen A.E., Silver R.I., Guileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. The Journal of Clinical Investigation 92 (1993) 903-910
26. Thomas LN L.C., Gupta R., Norman R.W., et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. The Prostate 63 3 (2005) 231-239
27. Raghow S H.M., Katiyar S., and Steiner M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Research 62 5 (2002) 1370-1376
28. Montironi R., Magi-Galluzzi C., Muzzonigro G., et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Journal of Clinical Pathology 47 (1994) 906-913
29. Bullock M.J., Srigley J.R., Klotz L.H., et al. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. American Journal of Surgical Pathology 26 (2002) 1400-1413
30. van der Kwast T.H., Labrie F., and Tetu B. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Human Pathology 30 (1999) 1503-1507
31. Ferguson J., Zincke H., Ellison E., et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44 (1994) 91-95
32. Vailancourt L., Ttu B., Fradet Y., et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. American Journal of Surgical Pathology 20 (1996) 86-93
33. Thompson I.M., Coltman Jr. C.A., and Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. The Prostate 33 (1997) 217-221
34. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine 349 (2003) 215-224
35. Thompson I.M., Lucia M.S., Redman M.W., et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. The Journal of Urology 178 (2007) 107-109 [discussion: 110]
36. Andriole G B.D., Brawley O., Gomella L., et al., REDUCE Study Group. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. The Journal of Urology 172 4 Pt 1 (2004) 1314-1317
37. Andriole G.L., Humphrey P., Ray P., et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. The Journal of Urology 172 (2004) 915-919
38. Yang X.J., Lecksell K., Short K., et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 53 (1999) 696-700
39. Civantos F W.R., Pinto J.E., Korman J.H., et al. Finasteride effect on prostate cancer: a comparative clincopathologic study of radical prostatectomies. Journal of Urologic Pathology 6 (1997) 1-8
40. Montironi R P.R., Diamanti L., Hamilton P.W., et al. Evaluation of prostatic intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor (finasteride). A methodologic approach. Analytical and Quantitative Cytology and Histology 18 6 (1996) 461-470
41. Iczkowski K.A., Qiu J., Qian J., et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65 (2005) 76-82
42. Price D., Stein B., Sieber P., et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. The Journal of Urology 176 3 (2006) 965-970